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Abstract Lymphatic vascular development involves specification of lymphatic endothelial
progenitors that subsequently undergo sprouting, proliferation and tissue growth to form a
complex second vasculature. The Hippo pathway and effectors Yap and Taz control organ growth
and regulate morphogenesis and cellular proliferation. Yap and Taz control angiogenesis but a role
in lymphangiogenesis remains to be fully elucidated. Here we show that YAP displays dynamic
changes in lymphatic progenitors and Yap1 is essential for lymphatic vascular development in
zebrafish. Maternal and Zygotic (MZ) yap1 mutants show normal specification of lymphatic
progenitors, abnormal cellular sprouting and reduced numbers of lymphatic progenitors emerging
from the cardinal vein during lymphangiogenesis. Furthermore, Yap1 is indispensable for Vegfc-
induced proliferation in a transgenic model of Vegfc overexpression. Paracrine Vegfc-signalling
ultimately increases nuclear YAP in lymphatic progenitors to control lymphatic development. We
thus identify a role for Yap in lymphangiogenesis, acting downstream of Vegfc to promote
expansion of this vascular lineage.
DOI: https://doi.org/10.7554/eLife.42881.001
Introduction
During embryonic development, the lymphatic vascular network derives chiefly from pre-existing
veins. In the E9-9.5 mouse embryo, complex, multicellular lymphatic vessels are ultimately generated
from a limited pool of lymphatic endothelial cell (LEC) progenitors first specified along the cardinal
veins (Oliver and Srinivasan, 2010; Wigle and Oliver, 1999). LEC progenitors sprout and progres-
sively colonise embryonic tissues over developmental time (Hägerling et al., 2013;
Koltowska et al., 2013). In the zebrafish trunk, a complex lymphatic vasculature is established within
just a few days and from a very limited number of progenitors (Koltowska et al., 2015a;
Nicenboim et al., 2015; Shin et al., 2016). Beginning from around 32–34 hr post fertilisation (hpf),
Grimm et al. eLife 2019;8:e42881. DOI: https://doi.org/10.7554/eLife.42881 1 of 22
RESEARCH ARTICLE
lymphangiogenesis generates a functional lymphatic network by 5 days post fertilisation (dpf)
(Hogan and Schulte-Merker, 2017). To allow this rapid development, multiple molecular pathways
have to instruct and orchestrate cellular behaviour as well as control the growth and proliferation of
the developing tissue.
Precursor cells in the cardinal vein obtain lymphatic identity upon induction of Prox1 expression,
a transcription factor that is essential for development of LECs in both mice and zebrafish
(Johnson et al., 2008; Koltowska et al., 2015a; Wigle and Oliver, 1999). Sprouting of LECs from
the cardinal veins is governed by Vegfc signalling acting through the endothelial receptor Vegfr3
(Flt4) in both mice and zebrafish (Hogan et al., 2009b; Karkkainen et al., 2004; Le Guen et al.,
2014; Veikkola et al., 2001; Villefranc et al., 2013). Zebrafish Vegfc and Vegfd also play partially
compensatory roles in both trunk and craniofacial lymphangiogenesis (Astin et al., 2014;
Bower et al., 2017). Underlining the conservation of this pathway in lymphangiogenesis, mutations
in VEGFC and VEGFR3 cause primary lymphedema in humans (Gordon et al., 2013; Irrthum et al.,
2000; Karkkainen et al., 2000). Ultimately, induction of Vegfr3 signalling in LECs by Vegfc triggers
the activation of multiple downstream intracellular signalling events involved in cell migration, sur-
vival and cellular proliferation (Deng et al., 2015; Zheng et al., 2014). In the zebrafish, Vegfc-Flt4
signalling acts to induce Prox1 expression at the earliest stages of lymphatic specification
(Koltowska et al., 2015a; Shin et al., 2016), although a role in specification remains to be fully
explored in the mouse model. Precisely how LECs contextually interpret growth factor signals and
elicit a number of different, specific cellular responses still remains to be fully understood.
Key regulators of normal and pathological organ and tissue growth are the Hippo pathway and
effector transcription factors, YAP and TAZ, which have been shown to promote proliferation, sup-
press apoptosis and modulate cellular and tissue morphogenesis (Harvey et al., 2013). YAP and its
paralogue TAZ are transcriptional co-factors that drive target gene expression by binding to the
TEAD1-4 transcriptional co-factors (Pobbati and Hong, 2013; Yu and Guan, 2013; Yu et al., 2015).
As potent drivers of cell proliferation, YAP and TAZ have been implicated as oncogenes that are
commonly upregulated in various cancer types including colon and breast cancer (Harvey et al.,
2013; Varelas, 2014). Thus, their activity has to be tightly regulated. The classical HIPPO pathway
inhibits YAP/TAZ signalling by retaining the effectors in the cytoplasm through the activation of a
phosphorylation cascade. The kinase MST1/2 phosphorylates another kinase LATS1/2, which subse-
quently phosphorylates YAP/TAZ. This phosphorylation sequesters YAP/TAZ in the cytoplasm and
leads to their degradation (Yu and Guan, 2013; Yu et al., 2015). Ultimately, YAP and TAZ function
in the cytoplasm, at cell-cell junctions and in the nucleus as core integrators of extracellular stimuli
such as growth factor signalling, mechanical forces and cellular adhesion (Panciera et al., 2017;
Varelas, 2014).
Recent studies have demonstrated that YAP and TAZ play important roles in vasculature
(Kim et al., 2017; Neto et al., 2018; Wang et al., 2017). While Yap knockout mice are lethal due to
developmental arrest of the embryo and severe defects in the yolk sac vasculature (Morin-
Kensicki et al., 2006), endothelial specific deletion of Yap and Taz leads to vascular defects due to
impaired EC sprouting and proliferation (Kim et al., 2017; Neto et al., 2018). In endothelial cells
(ECs), nuclear YAP/TAZ promotes proliferation and cell survival while retention of YAP/TAZ in the
cytoplasm leads to apoptosis (Panciera et al., 2017; Zhao et al., 2011). Moreover, it has been sug-
gested that YAP/TAZ in blood vascular ECs regulate angiogenesis downstream of VEGFA both by
modulating cellular proliferation and controlling adherens junctional dynamics during vessel morpho-
genesis (Neto et al., 2018; Wang et al., 2017). Roles for Yap and Taz have been recently shown in
lymphatic vessel morphogenesis in development and postnatal settings in mice, but the mechanisms
of action remain to be fully appreciated (Cho et al., 2019). YAP has further been found to respond
to altered flow patterns in zebrafish and in cultured blood and lymphatic ECs (Nakajima et al.,
2017; Sabine et al., 2015). Yap1 also contributes to blood vessel maintenance in zebrafish, although
blood vessels still undergo normal angiogenesis in zebrafish yap1 mutant models (Nakajima et al.,
2017). Despite important roles in the vasculature, in the context of early embryonic lymphatic vascu-
lar development, roles for Yap and Taz remain to be fully explored.
Here we utilise zebrafish mutants and live imaging of zebrafish reporters of YAP activity to show
that Yap1 is indispensable for lymphatic vascular development. Yap1 acts in a cell autonomous man-
ner and is necessary at stages of lymphangiogenesis driven by Vegfc/Flt4 signalling. However, unlike
mutants in the Vegfc/Flt4 pathway Yap1 mutants display normal specification of Prox1-positive
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lymphatic progenitors coincident with aberrant cellular behaviours during LEC sprouting. We identify
a central role for Yap1 in Vegfc-induced EC proliferation and show that the nuclear concentration of
YAP changes dynamically in lymphatic progenitors, driven by Vegfc. This work suggests a dynamic
signalling mechanism integrating Vegfc/Flt4 signalling with Yap1 control of LEC proliferation and cel-
lular behaviour during trunk lymphatic vascular development.
Results
YAP is active in developing lymphatics of the zebrafish trunk
To investigate whether zebrafish LEC progenitors display Yap1/Taz signalling, we made use of the
previously published transgenic line, Tg(fli1:Gal4db-TEAD2DN-2A-mCherry); Tg(UAS:GFP), hereafter
called the TEAD reporter (Nakajima et al., 2017). This line reports expression when active, endoge-
nous Yap1 binds to the synthetic TEAD-Gal4db protein and subsequently drives EGFP expression
from a UAS element. Expression was detected throughout the dorsal aorta (DA), the intersegmental
vessels (ISVs) and PCV at 30 hpf, parachordal LEC progenitors (PLs, 2 dpf) and the thoracic duct at 5
dpf (Figure 1A,B, Video 1).
TEAD-reporter activity is observed via a stable EGFP protein, thus does not accurately report
dynamic activity of Yap1. Hence, we used Tg(fli1a:EGFP-YAP);(fli1a:H2B-mCherry) (Nakajima et al.,
2017), hereafter referred to as the YAP reporter line, which expresses human YAP fused to EGFP in
zebrafish vasculature. YAP is regulated at the level of entry into the nucleus and EGFP-YAP used
here has been shown to accurately reflect endogenous YAP (Bao et al., 2011; Nakajima et al.,
2017). We analysed EGFP-YAP fluorescence intensity (average pixel intensity per nucleus) in the
nuclei of PLs relative to the intensity of nuclear H2B-mCherry in the same cells using two different
methods (Figure 1C–G, see Materials and methods for details). Firstly, the EGFP/mCherry fluores-
cence intensity ratio was calculated in 3D, using automated surface masking of the nucleus and mea-
suring the intensities for both channels spanning the full z-stack (Figure 1F and G). Secondly,
fluorescence intensity was extracted from a single Z-plane (2D) at the centre of each nucleus (Fig-
ure 1—figure supplement 1A and D). Both approaches revealed concordant results (Figure 1—fig-
ure supplement 1E). We found nuclear EGFP-YAP in PL nuclei that was highly variable between PLs
within the same embryo (relative to H2B-mCherry), despite both proteins being driven from the fli1a
promoter (Figure 1C–G). Furthermore, we estimated the nuclear to cytoplasmic ratios for EGFP-YAP
between PLs (for the same embryos quantified in Figure 1F). We found that differences in the
nuclear concentration of EGFP-YAP between PLs (calculated as nuclear EGFP-YAP/mCherry) corre-
lated with differences in the nuclear-cytoplasmic ratio of EGFP-YAP (Figure 1H and Figure 1—fig-
ure supplement 1B–C). This suggests that measurement of nuclear concentration can reflect and
serve as a proxy for cytoplasm-nuclear changes. Given the above findings, the variable nature of EC
cytoplasmic distribution, and relative accuracy of nuclear measurements, all further analyses use
changes in nuclear concentration as a proxy for changes in YAP activity.
Interestingly, when we measured nuclear EGFP-YAP intensities using high speed spinning disc
microscopy, we found that EGFP-YAP did not change or fluctuate rapidly over short developmental
time periods (imaged over 90 min of development) (Figure 1—figure supplement 1F–F”, Video 2).
However, quantification of nuclear EGFP-YAP levels in individual PLs over longer periods of develop-
ment revealed dynamic changes (Video 3, Figure 1I, Figure 1—figure supplement 1G). Detailed
cell tracking analyses showed that these changes were not associated simply with breakdown of the
nuclear lamina during cell division (Figure 1I (arrow in cell track two indicates a cell division), Fig-
ure 1—figure supplement 1G). Taken together, these observations suggest that YAP is dynamically
regulated in PLs during lymphatic development.
Yap1 cell autonomously regulates lymphangiogenesis in the zebrafish
trunk
We next examined the formation of the lymphatic vasculature in yap1 mutants. We analysed two dif-
ferent mutant strains: yap1ncv101-/- mutants have a 25 bp deletion in exon1 leading to a frame shift
and stop codon after 71 bp, prior to the TEAD binding domain (Nakajima et al., 2017) and
yap1mw48-/- mutants display a 4 bp deletion after 158 bp, truncating the TEAD binding domain and
leading to a premature stop codon (Miesfeld et al., 2015). Analysis of the two alleles revealed
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Figure 1. Nuclear EGFP-YAP changes dynamically in the developing trunk lymphatic vasculature. (A–B) The TEAD reporter line [Tg(fli1:Gal4db-
TEAD2DN-2A-mC);(UAS:GFP)] shows Yap1 activity in vasculature, parachordal LECs (PLs) and cardinal vein sprouts (arrowhead) of the 2 dpf trunk (A) as
well as in the thoracic duct (TD) at 5 dpf (B). Scale bars: 40 mm. (C) Maximum projection of 8 PLs in a two dpf embryo showing EGFP-YAP in green [Tg
(fli1:EGFP-YAP)] and the nucleus in red (C’), [Tg(flil:H2B-mCherry)] and merge (C”’). Scale bar: 25 mm. (D–E) High power single z-sections of selected PLs
from C, showing nuclear YAP in PL2 and PL3, but low nuclear YAP in PL4 (D–D’) and PL7 (E–E’). Scale bars: 10 mm. (F) Quantification of nuclear EGFP/
mCherry average pixel intensity across individual PLs from multiple embryos at 2 dpf. Each bar represents a single PL (n = 47), each grey shade a
different embryo (n = 5). PLs in (C and D) highlighted in the green box. EGFP/mCherry Ratios have been calculated using mean fluorescent intensities
in 3D. (G) Scatter Plot of the Nuclear EGFP/mCherry average pixel intensity for individual PLs (n = 5 embryos). Each colour indicates PLs from a different
embryo. Values calculated in 3D measurements of the mean fluorescent intensity for EGFP and mCherry (0.66 ± 0.04, n = 47). (H) Pearson Correlation
Plot of the Nuclear EGFP/mCherry Ratio values in F and the Nuclear/Cytoplasmic EGFP Ratio values in Figure 1—figure supplement 1B (r = 0.52, 95%
confidence intervals: 0.27 to 0.70, R square = 0.27, p=0.0002(***)). The two distinct approaches produce correlative measurements. (I) Average nuclear
pixel intensity graphs from cell tracks of single PLs time-lapse imaged from 2 to 3 dpf. EGFP-YAP intensity (green) is compared over time with H2B-
mCherry (red) intensity in individual nuclei. Arrow points to a cell division during time-lapse.
DOI: https://doi.org/10.7554/eLife.42881.002
The following source data and figure supplements are available for figure 1:
Source data 1. Measurements of EGFP-YAP in PLs.
DOI: https://doi.org/10.7554/eLife.42881.005
Figure supplement 1. Measurements of EGFP-YAP intensity in lymphatic progenitor nuclei over time.
DOI: https://doi.org/10.7554/eLife.42881.003
Figure supplement 1—source data 1. Methodological Analysis of EGFP-YAP Intensities in PLs.
DOI: https://doi.org/10.7554/eLife.42881.004
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equivalent phenotypes. Yap1 is maternally depos-
ited and zygotic yap1 mutants (Zyap1-/-) are via-
ble (Cox et al., 2016). Using transgenic lines to
visualise developing veins and lymphatics
(TgBAC(dab2b:EGFP)ncv67, Tg(kdrl:mCher-
ry)ncv502), we observed only subtle lymphatic
defects in Zyap1ncv101-/- mutants with a minor
reduction in thoracic duct formation (Figure 2—
figure supplement 1A,C). To completely deplete
the embryo of Yap1, we generated maternal
zygotic (MZyap1-/-) mutants in several transgenic
backgrounds by crossing heterozygous males to
homozygous mutant females. Strikingly, while the
overall morphology of MZyap1-/- mutants at 5
dpf appeared relatively normal with mutant
embryos displaying subtle craniofacial defects
and a missing swim bladder (Figure 2A),
MZyap1-/- mutants failed to form a mature trunk
lymphatic vasculature (Figure 2B–E). However,
the craniofacial lymphatic network had devel-
oped normally (Figure 2—figure supplement
1B, D) and blood flow remained intact and func-
tional with apparently normal morphology of blood vessels in the 5 dpf trunk (Figure 2B–C). To fur-
ther investigate whether the MZyap1-/- mutants displayed any abnormalities in the formation of the
blood vasculature, we analysed angiogenic sprouting at 24 and 32 hpf (Figure 2—figure supple-
ment 2). Compared with wildtype siblings, MZyap1-/- mutants had a transient, mild reduction in the
number of EC nuclei in intersegmental vessel (ISV) sprouts (Figure 2—figure supplement 2A,D,E),
prominent in the most posterior sprouts analysed (Figure 2—figure supplement 2F) at 24 hpf. How-
ever, the number of ECs in each vessel had largely recovered by 32 hpf (Figure 2—figure supple-
ment 2B,D,E,F). Furthermore, we could see
normal lumenisation of blood vessels in
MZyap1-/- mutants (Figure 2—figure supple-
ment 2C).
The above observations indicate that yap1 is
necessary to form a lymphatic vasculature, but
not blood vasculature. To test whether Yap1
function is cell autonomous in ECs, we next
transplanted wildtype or mutant Tg(fli1a:EGFP)
Video 1. Time-lapse Video of the developing trunk
vasculature of Tg(fli1:Gal4db-TEAD2DN-2A-mC);(UAS:
GFP)] from 30 hpf – 2 dpf. The EGFP signal can be
seen to diminish in major trunk blood vessels but
remains strong in the dorsal posterior cardinal vein
(PCV) and parachordal LECs (PLs).
DOI: https://doi.org/10.7554/eLife.42881.006
Video 2. High-speed time-lapse Video of the
developing parachordal LECs (PLs) in [Tg(fli1a:EGFP-
YAP),(fli1a:H2B-mCherry)] embryos from 2 dpf. EGFP-
YAP signal remains relatively stable over the imaged
time period of 90 min. Z-stacks were acquired every
minute. Fluorescence intensity of EGFP diminishes due
to mild bleaching over time. The right panel shows the
EGFP fluorescent intensity as a heatmap within the PL
nuclei.
DOI: https://doi.org/10.7554/eLife.42881.007
Video 3. Time-lapse Video of developing parachordal
LECs (PLs) in [Tg(fli1a:EGFP-YAP),(fli1a:H2B-mCherry)]
embryos from 2 to 3 dpf with images acquired in 20–22
min intervals. The EGFP-YAP signal in individual PLs
changes over time as shown in the lower panel
displaying a heatmap of the nuclei. Dorsal aorta (DA),
posterior cardinal vein (PCV).
DOI: https://doi.org/10.7554/eLife.42881.008
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Figure 2. Yap1 acts cell autonomously to control trunk lymphangiogenesis in zebrafish. (A) Overall morphology of sibling (left) and MZyap1ncv101-/-
mutant (right) at 5 dpf. Arrowheads indicate mild craniofacial defects and absent swim bladder. Scale bar 200 mm. (B–C) Trunk vasculature of sibling and
MZyap1ncv101-/- mutant embryos at 5 dpf. Veins and lymphatics are displayed in white [Tg(dab2b:EGFP)], erythrocytes show normal blood flow in red [Tg
(gata1:DsRed)]. Asterisks mark absent lymphatic vessels. (C) Trunk vasculature of sibling and MZyap1mw48-/- mutant at 6 dpf. Vascular nuclei are marked
Figure 2 continued on next page
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ECs into wildtype or mutant Tg(fli1a:myrmCherry) hosts (Figure 2F–G). Subsequently, we selected
embryos with EC grafts and scored grafts of similar size (Figure 2H). We scored the contribution of
ECs in vascular grafted embryos to arterial, venous and lymphatic vessels (Figure 2I). Across n = 23
wildtype EC grafts, ECs contributed to arterial and venous structures as well as to lymphatic vessels
at frequencies equivalent to those we have previously reported (Koltowska et al., 2015b). Across
n = 24 mutant EC grafts, MZyap1-/- mutant ECs were able to form arterial grafts at frequencies com-
parable to wildtype EC grafts. However, MZyap1-/- mutant ECs formed venous grafts at a slightly
reduced frequency and failed to contribute to lymphatic vessels except for small numbers of cells in
just n = 2/24 transplanted embryos (compared with n = 10/23 robust contributions in embryos trans-
planted with WT cells) (Figure 2G–I). Overall, this indicates that Yap1 has a cell autonomous role in
trunk lymphangiogenesis.
Yap1 is dispensable for specification but essential for sprouting and
Vegfc-induced proliferation of LECs
LEC progenitors sprout from the PCV in a Vegfc/Flt4 dependent manner and colonise the HM tran-
siently, a period when they are highly proliferative as well as migratory (Bussmann et al., 2010;
Cha et al., 2012; Koltowska et al., 2015a; Yaniv et al., 2006). We scored MZyap1-/- mutants for
ECs sprouting from the PCV at 2 dpf and found a reduction in the total number of ECs departing
the vein (Figure 3A–B). Strikingly, we saw almost a complete loss of PLs, but near normal numbers
of ECs in venous intersegmental blood vessels (Figure 3A,C,D). By 3 dpf, PL numbers in the HM
remained reduced but showed recovery compared with sibling controls (Figure 3E). To investigate
whether this reduction in PL numbers is a result of reduced LEC progenitor specification, we exam-
ined Prox1 expression as a marker of LEC fate. We found that Prox1 expression in the PCV and LECs
departing the PCV was unchanged at 36 hpf (Figure 3F,G). Thus, Yap1 is not required for the induc-
tion of lymphatic identity but is needed to establish normal numbers of LECs in sprouts arising from
the PCV.
To further investigate the cellular behaviours controlled by Yap1, we performed time-lapse imag-
ing from 32 to 65 hpf. We visualised sprouting LECs using Tg(lyve1b:dsRed2; fli1a:nlsEGFP), which
Figure 2 continued
in green [Tg(fli1a:nEGFP)], venous and lymphatic vessels in white [Tg( 5.2lyve1b:DsRed)]. Asterisks indicate absent lymphatic vessels. Scale bars: 50 mm
in B and C. (D) Percentage of TD fragments formed per somite, scored across six somites in total for siblings and MZyap1ncv101-/-mutants at 5 dpf
(sibling: 100% ± 0, n = 23; MZyap1ncv101-/-: 49% ± 7.33, n = 22; p,0.0001). (E) Quantification of the total number of LECs across 6 somites at 6 dpf
(sibling: 37 ± 1.91, n = 11; MZyap1mw48-/-: 8 ± 3.79; p<0.0001). (F) Schematic showing the cell transplantation technique. Blastomere cells are
transplanted from donor (EGFP) into host (mCherry) embryos. This results in a chimeric host embryo (right) with randomly located, transplanted EC
grafts. (G) Representative images of host chimeric trunk vessels at 5 dpf. Wildtype (wt) donor ECs contribute to all vascular EC types, while
MZyap1ncv101-/- mutant ECs show reduced propensity to contribute to lymphatic structures. Asterisk marks missing TD. Scale bars: 50 mm. (H) Graft sizes
analysed for vascular grafts. Numbers within bars represent the number of embryos scored for each graft size. (I) Percentage of embryos with EC grafts
contributing to arterial (wt into wt: 96% ± 4; MZyap1ncv101-/- into wt: 100% ± 0; p=0.31, not significant (ns)), venous (wt into wt: 91% ± 6; MZyap1ncv101-/-
into wt: 67% ± 10; p=0.04 (*)) and lymphatic vessels (wt into wt: 43% ± 10; MZyap1ncv101-/- into wt: 8% ± 6; p=0.005 (**)). Wildtype into wildtype total
number of EC grafts: n = 23; MZyap1ncv101-/- mutant into wildtype total number of EC grafts: n = 24. Dorsal aorta (DA); Posterior Cardinal Vein (PCV);
Thoracic Duct (TD); Intersegmental Lymphatic vessel (ISLV), Dorsal Longitudinal Lymphatic vessel (DLLV).
DOI: https://doi.org/10.7554/eLife.42881.009
The following source data and figure supplements are available for figure 2:
Source data 1. Measurements for the lymphatic phenotype of the MZyap1-/-mutant.
DOI: https://doi.org/10.7554/eLife.42881.014
Figure supplement 1. Zyap1-/- mutants only exhibit mild lymphatic defects in the trunk and MZyap1-/- mutants form facial lymphatics.
DOI: https://doi.org/10.7554/eLife.42881.010
Figure supplement 1—source data 1. Quantification of the lymphatic phenotype of the Zyap-/- mutant trunk and MZyap1-/-mutant craniofacial
phenotype.
DOI: https://doi.org/10.7554/eLife.42881.011
Figure supplement 2. MZyap1-/- mutants do not show major defects in blood vessel formation.
DOI: https://doi.org/10.7554/eLife.42881.012
Figure supplement 2—source data 1. Characterisation of angiogenic sprouting in the MZyap1-/-mutants.
DOI: https://doi.org/10.7554/eLife.42881.013
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Figure 3. MZyap1-/- mutants display defects in LEC numbers but not specification. (A) Trunk vasculature (EC nuclei in green, veins and lymphatics in
white) of sibling and MZyap1mw48-/- mutant at 2 dpf. Arrowheads indicate posterior cardinal vein (PCV) sprouts. Asterisks mark absent parachordal LECs
(PLs). Dorsal aorta (DA). Scale bars: 50 mm. (B) Total number of lyve1-positive ECs departing the PCV across 6 somites at 2 dpf. (C) Number of
endothelial cells in venous intersegmental vessels (vISV) across 6 somites at 2 dpf (sibling: 13 ± 0.94, n = 14; MZyap1-/-: 12 ± 1.33, n = 14; p=0.24 (ns)).
Figure 3 continued on next page
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at these stages spans the period of first detection of dsRed2 expression (Figure 3H, Videos 4–
6). We observed striking abnormal behaviours of sprouts arising from the PCV in MZyap1-/- mutants,
most commonly sprouts appeared thickened, retracted, or turned ventrally and formed abnormal
loops (Video 5, mutant 1). Often venous sprouts formed abnormal connections with other venous
sprouts from adjacent body segments (Video 6, mutant 2). These abnormal behaviours and reduced
sprouting cell numbers likely contribute to fewer PLs accurately seeding the HM during
development.
Yap1 mediates Vegfc-driven proliferation in venous-derived endothelial
cells
YAP is established to control cellular proliferation in diverse contexts, including in ECs
(Panciera et al., 2017; Zhao et al., 2011). To ask whether Yap1 plays a role in EC proliferation
downstream of Vegfc in PLs, as well as mediating normal sprouting behaviour, we used a transgenic
approach. We overexpressed vegfc throughout the trunk under the control of the prox1a promoter
(using TgBAC(prox1a: KalTA4-4xUAS-ADV.E1b:TagRFP)nim5, Tg(10xUAS:vegfc)uq2bh double trans-
genic (vegfc-OE) embryos), which is active in tissues that include muscle, neurons and vasculature
(Koltowska et al., 2015a; van Impel et al., 2014). We then injected a yap1 targeting morpholino
(MO) that has been previously validated (Loh et al., 2014) and phenocopied MZyap1-/- mutants
(Figure 4A,C and data not shown). vegfc overex-
pression resulted in hyper-proliferation of
venous-derived ECs throughout the trunk includ-
ing prominently in the HM, where excessive
numbers of ECs proliferate as previously
described (Figure 4B,C, Koltowska et al.,
2015a). The effect of Vegfc stimulation was
completely blocked upon yap1 MO injection but
not upon p53 (control) MO injection (Figure 4B,
C). Together, these observations are consistent
with a role for Yap1 downstream of Vegfc, func-
tioning in Vegfc-induced proliferation.
To further validate this observation made
with MO-mediated knockdown, we tested the
ability of elevated Vegfc-induced signalling to
stimulate PL proliferation in MZyap1-/- mutant
embryos. We transplanted cells at blastula
stages from vegfc-OE transgenic donor embryos
into wildtype and MZyap1-/- mutant embryos
(Figure 4D–E). Embryos that had engrafted
vegfc-OE cells in muscle adjacent to the HM
were then selected for analysis. The number of
PLs responding to the local graft were scored
Figure 3 continued
(D) Number of PLs scored across 6 somites at 2 dpf (sibling: 3 ± 0.56, n = 14; MZyap1-/-: 0.36 ± 0.23, n = 14; p<0.0001 (****)). (E) Number of PLs scored
across 6 somites at 3 dpf (sibling: 4.5 ± 0.20, n = 14; MZyap1-/-: 3.31 ± 0.36, n = 13; p=0.0075(**)). (F) Immunofluorescence staining for EC nuclei (green)
and Prox1 (red) in sibling and MZyap1mw48-/- mutants at 36 hpf. Arrows point to Prox1+ LEC progenitors. Scale bars: 30 mm. (G) Quantification of
Prox1 +cells in PCV and CV sprouts scored across 6 somites at 36 hpf (sibling: 3.47 ± 0.65, n = 19; MZyap1-/-: 3.31 ± 0.61, n = 16; p=0.86 (ns)). (H)
Maximum projection stills from time-lapse Videos from 32 to 65 hpf. Sibling still images show normal lymphangiogenesis with PCV sprouts, PL
formation, sprout detachment and PL proliferation (upper panels). MZyap1mw48-/- mutant one displays abnormal sprouting and looping of PCV sprouts
that are retained until the end of the Video (central panels). MZyap1mw48-/- mutant two also exhibits abnormal sprouting and PCV loop formation but
also forms PLs (lower panels). Scale bars: 25 mm. Timelapse imaging began at 32 hpf.
DOI: https://doi.org/10.7554/eLife.42881.015
The following source data is available for figure 3:
Source data 1. Cell counts for PCV-derived cells in the MZyap-/- mutants.
DOI: https://doi.org/10.7554/eLife.42881.016
Video 4. Time-lapse Video of the trunk vasculature of a
sibling from 32 to 65 hpf in the [Tg(fli1a:nEGFP);
( 5.2lyve1b:DsRed2)] background showing endothelial
nuclei in green and lymphatic and venous endothelium
in red. Normal lymphangiogenesis involves sprouting
from the posterior cardinal vein (PCV) to form PLs at
the horizontal myoseptum. Dorsal aorta (DA). Scale bar:
25 mm.
DOI: https://doi.org/10.7554/eLife.42881.017
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within the same body segment in wildtype and MZyap1-/- mutant embryos at 3 dpf. Strikingly, the
MZyap1-/- mutant host embryos displayed a vast reduction (although not a complete block) in num-
bers of proliferative PLs adjacent to HM grafts compared with wildtype siblings (Figure 4F,G). These
data, coupled with reduced numbers of ECs in sprouts departing the PCV (Figure 3B), together sug-
gest that Yap1 plays a role in the proliferation of developing lymphatic progenitors stimulated by
Vegfc.
Vegfc signalling promotes nuclear YAP in LEC progenitors
Nuclear localisation of YAP has been linked to EC proliferation (Panciera et al., 2017). We specu-
lated that Vegfc signalling might promote nuclear Yap1 in order to promote LEC proliferation. To
test this, we used a transplantation approach and transplanted vegfc-overexpressing cells (labelled
by TagRFP in host embryos) at blastula stages into embryos carrying the EGFP-YAP reporter
(Figure 5A). We selected embryos with labelled vegfc-OE neurons or muscle cells and found that
these grafts were sufficient to induce local proliferation of adjacent venous ECs and LEC progenitors
(Figure 5B,C). We analysed the localisation of EGFP-YAP in responding PLs local to Vegfc-producing
donor cells. To generate an unbiased quantification that allows for variation in transgene intensity
between embryos, we scored nuclear EGFP intensity in dorsal aorta cells (DA) and used the average
pixel intensity of the DA cells as vegfc-OE unresponsive internal controls (see Koltowska et al.,
2015a). Thus, PL nuclear EGFP intensity is calculated as PL nuclear intensity/average DA nuclear
intensity in the same embryo (Figure 5C’,D). We found that Vegfc responsive PLs displayed an
increase in nuclear EGFP-YAP compared with control PLs (Figure 5C’,D). This increase in nuclear
EGFP-YAP in the vegfc-OE transplanted embryos was concomitant with a higher number of PLs
(Figure 5G). Control PLs were scored in embryos transplanted with donor cells expressing the Kalt4
driver but not carrying the UAS:vegfc element (Figure 5B–D,F–G). Further, we transplanted from
EGFP-YAP reporter donor embryos into vegfc-OE and control recipient embryos (Figure 5—figure
supplement 1A). We selected small vascular EC grafts and examined grafted LECs and VECs for
EGFP-YAP nuclear concentration. Relative to nuclear concentration in grafted vegfc-unresponsive
DA cells, EGFP-YAP was increased in nuclei in lymphatic and venous EC grafts in the vegfc-OE hosts
(Figure 5—figure supplement 1B–E).
Finally, as Vegfc/Flt4 signalling has been previously shown to be transduced via Erk in zebrafish
trunk vasculature (Koltowska et al., 2015a; Shin et al., 2016), we investigated the impact of block-
ing this pathway on EGFP-YAP in PLs. Treatment with SL327, a MEK inhibitor that blocks Erk signal-
ling in zebrafish (Shin et al., 2016), decreased the concentration of EGFP-YAP in the nuclei of PLs,
concomitant with a reduction in PL number (Figure 5E,H–J). This was observed using time-lapse Vid-
eos (Figure 5H, not shown) as well as acquiring images following a single 12 hr treatment to exclude
interference from time-lapse bleaching (Figure 5I). Overall, these observations indicate that the
Vegfc-Erk axis promotes high nuclear Yap1 and drives normal sprouting and proliferation during
zebrafish developmental lymphangiogenesis.
Discussion
Hippo pathway signalling and YAP/TAZ activity are key regulators of cell proliferation and organ
growth and pathway components are frequently dysregulated in cancer (Harvey et al., 2013).
Recent research has broadened our understanding of this pathway, which can function to integrate
stimuli from the cellular environment that ultimately affect cell migration, growth and even cell fate
(Panciera et al., 2017). In ECs, YAP/TAZ signalling has been relatively understudied, yet has still
been reported to have roles in proliferation, survival, migration, adhesion and cellular rearrange-
ments, although the mechanisms that utilise YAP are not completely understood (Kim et al., 2017;
Neto et al., 2018; Wang et al., 2017). We show here that loss of Yap1 has a dramatic effect upon
lymphatic vascular development, as MZyap1-/- mutants fail to form a lymphatic network in the zebra-
fish trunk. Surprisingly, these mutants exhibit a largely normal blood vasculature. The severity of the
MZyap1-/- mutant phenotype indicates that Yap1 is indispensable for lymphangiogenesis and its
paralogue Taz is not able to fully compensate in lymphatic vasculature. While not studied here, it
remains possible that Taz may compensate for the absence of Yap1 in some vascular beds (eg.
blood vessels) and not others (eg. lymphatics). It is also possible that there are tissue specific effec-
tors of Yap1 in lymphatic endothelial cells by comparison to other vascular lineages. Further work is
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clearly needed to determine the mechanisms
underlying the restricted lymphatic phenotype
that we have observed here.
Lymphatic endothelial progenitor cells are
specified in MZyap1-/- mutants but these fail to
sprout normally to the horizontal myoseptum.
The processes that are necessary for departure of
LEC progenitors from the PCV and seeding of
the HM include cell sprouting and directional
migration, both Vegfc-dependent
(Koltowska et al., 2015a; Nicenboim et al.,
2015). Mutants displayed variable and abnormal
cell behaviours including turning of sprouts back
towards the PCV and fusion of adjacent sprouts.
What the precise role of Yap1 is in venous EC
sprouting requires further study, yet recent work
points to regulation of junctional dynamics and
cellular elongation as candidate cellular pro-
cesses in other vessel contexts (Neto et al.,
2018).
In addition to sprouting defects, we see a gen-
eral reduction in the number of ECs that depart the PCV during secondary angiogenesis in the
MZyap1-/- mutants. We further show that Vegfc-induced VEC and PL proliferation (in a transgenic
overexpression model) requires normal levels of Yap1. In previous studies of blood vascular ECs, the
Yap/Taz dependent proliferative response was regulated by Yap/Taz localization in the nucleus,
where they regulate transcription to promote cell proliferation (Neto et al., 2018; Sakabe et al.,
2017; Wang et al., 2017). Here, we report that EGFP-YAP localises to the nuclei of early LEC pro-
genitors in zebrafish. Moreover, in vivo live imaging showed that dynamic changes occur in EGFP-
YAP protein concentration in lymphatic progenitor nuclei. This may indicate active regulation of
nuclear-cytoplasmic localisation of Yap1, as has recently been live-imaged in Drosophila
(Manning et al., 2018). Directly imaging nuclear-cytoplasmic shuttling of EGFP-YAP presented chal-
lenges, chiefly the highly variable morphology of PL cytoplasm, which limited us to calculations and
image analysis in 2D and may have introduced technical variation. Nevertheless, nuclear/cytoplasmic
EGFP-YAP measurements correlated with changes in nuclear concentration of EGFP-YAP between
PLs (Figure 1 and Figure 1—figure supplement
1) and confirmed that PLs display highly variable
concentrations of nuclear EGFP-YAP that likely
reflect differences in Yap1 activation and
upstream signalling. We also note that we did
not observe enrichment of EGFP-YAP fusion pro-
tein at cell-cell junctions and we note a caveat
that YAP may also be regulated at the level of
protein turnover. Importantly, a high concentra-
tion of nuclear EGFP-YAP was promoted by a
local source of Vegfc, concomitant with
increased PL proliferation (Figure 5 and Fig-
ure 5—figure supplement 1). Inhibition of Flt4-
dependent Erk signalling also reduced the
nuclear concentration of EGFP-YAP (Figure 5E–
J). This suggests overall that paracrine Vegfc sig-
nalling activates LEC progenitor Flt4/Erk-signal-
ling and that Yap1 is an essential effector of this
pathway.
The development of the lymphatic vascula-
ture is a remarkable process whereby a limited
pool of progenitor cells in the wall of functional
Video 5. Time-lapse Video of MZyap1mw48-/- mutant 1
from 32 to 65 hpf with endothelial nuclei in green and
lymphatic and venous endothelium in red. Abnormal
sprouts emerge from the posterior cardinal vein (PCV).
Dorsal aorta (DA). Scale bar: 25 mm.
DOI: https://doi.org/10.7554/eLife.42881.018
Video 6. Time-lapse Video of the trunk vasculature in
MZyap1mw48-/- mutant 2 from 32 to 65 hpf, showing
endothelial nuclei in green and lymphatic and venous
endothelium in red. Abnormal sprouts emerge from
the posterior cardinal vein (PCV) anddisplaying loops as
well as fusions with adjacent sprouts. Dorsal aorta (DA).
Scale bar: 25 mm.
DOI: https://doi.org/10.7554/eLife.42881.019
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Figure 4. Yap1 mediates endothelial cell proliferation downstream of Vegfc. (A) Trunk vasculature at 3 dpf displaying endothelial cells (ECs) in green
from uninjected, p53 morpholino (MO) injected and p53 +yap1 MO injected embryos. Asterisks highlight missing parachordal LECs (PLs). Scale bars: 50
mm. (B) Trunk vasculature at 3 dpf from uninjected, p53 MO injected and p53 +yap1 MOs injected embryos of the Tg(prox1a:KalT4xUAS:uncTagRFP);
Tg(10xUAS:vegfc) strain. yap1 MO injection rescues the EC proliferation phenotype. ECs in green. Asterisks mark missing PLs. Scale bars: 50 mm. (C)
Figure 4 continued on next page
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embryonic blood vessels are utilised as progenitors to generate a complex second vasculature. This
inherently presents a tissue growth event that requires extensive, coordinated cellular proliferation
coincident with network morphogenesis. That the HIPPO pathway and YAP would play a role follows
a clear biological rationale. The process of lymphangiogenesis is important in a swathe of disease
settings that include in common cardiovascular diseases and in the metastatic spread of cancer
(Petrova and Koh, 2018). In the later setting, excessive lymphangiogenesis underpins metastatic
spread and is a target of interest for inhibition (Dieterich and Detmar, 2016). Excessive lymphangio-
genesis is also a target of interest in rare diseases such as lymphangioma or lymphatic malformation.
While much emphasis in the development of anti-lymphangiogenic agents has focused on targeting
VEGFC/VEGFR3 signalling, pathways involved in tissue growth and cellular proliferation such as the























































Continued on next page
Figure 4 continued
Quantification of total EC number across four somites in vegfc-unstimulated (uninjected: 343 ± 9, n = 18; p53 MO: 341 ± 9, n = 18; p53 +yap1 MOs:
248 ± 15, n = 18; p<0.0001(****)) and vegfc-stimulated embryos (uninjected: 811 ± 35, n = 18; p53 MO: 794 ± 38, n = 18; p53 +yap1 MOs: 212 ± 10,
n = 18; p<0.0001(****)). (D) Schematic representation of vegfc-overexpressing cell transplantations for single muscle grafts in [Tg(fli1a:nEGFP);
( 5.2lyve1b:DsRed2)] hosts of siblings and MZyap1mw48-/- mutants. (E) Schematic of transplanted host embryo at 3 dpf. Muscle grafts produce excessive
Vegfc causing a hyperproliferation response in adjacent PLs. (F) Quantification of PL number within one somite responding to the vegfc-OE single
muscle graft at 3 dpf (sibling: 23.00 ± 1.19, n = 18; MZyap1mw48-/-: 6.36 ± 0.71, n = 22; p<0.0001 (****)). (G) Examples of 3 different vegfc-OE muscle
grafts (false coloured) in siblings (left panels) and MZyap1mw48-/- mutants (right panels). Merge images show ECs in green, lymphatic and venous ECs
are red (yellow) [Tg(fli1a:nEGFP);( 5.2lyve1b:DsRed2)]. Scale bars: 25 mm.
DOI: https://doi.org/10.7554/eLife.42881.020
The following source data is available for figure 4:
Source data 1. Measurements of ECs in Vegfc-overexpression embryos.
DOI: https://doi.org/10.7554/eLife.42881.021
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Figure 5. Vegfc promotes nuclear Yap1 in developing lymphatic progenitors. (A) Schematic showing the transplantation of vegfc-OE cells into EGFP-
YAP reporter hosts. (B) Trunk vasculature of YAP reporter host embryos with neuron and muscle grafts expressing RFP (magenta) at 56 hpf. Control
grafts (left) and vegfc-OE grafts (right). Posterior cardinal vein (PCV); Muscle (M); parachordal LECs (PLs); Neuron (N). Scale bars: 50 mm in B and C. (C)
Heatmaps of maximum projections of EGFP-YAP from B) showing PLs and PCV. Red corresponds to high EGFP-YAP fluorescence. (C’) Lower panels
Figure 5 continued on next page
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Figure 5 continued
show heatmaps of EGFP-YAP in PL nuclei. (D) EGFP intensity for each PL expressed as a ratio to the average of 6 dorsal aorta (DA) cells (unresponsive
to vegfc). six embryos per group: untransplanted host (control) (PL n = 27), transplanted control without the UAS:vegfc construct (TP Control) (PL n = 40)
and vegfc-OE transplanted embryos (TP vegfc-OE) (PL n = 251). Individual embryos indicated by an individual grey shade. (E) Heatmaps of EGFP-YAP
depicting PL nuclei of embryos at 66 hpf that were treated with DMSO (left) and SL327 for 13 hr (hrs) (right). Max projections are from time-lapse
Videos. Scale bars: 30 mM. (F) EGFP mean intensity for each PL/DA in panel D (Control: 1.61 ± 0.13, n = 27; TP Control: 1.93 ± 0.12, n = 40; p=0.08 (ns);
TP vegfc-OE: 3.14 ± 0.07, n = 251; p<0.0001(****)). (G) Quantification of PL number across six somites for each group (Control: 5 ± 0.26, n = 6; TP
Control: 8 ± 0.78, n = 16; p=0.0157 (*); TP vegfc-OE: 44 ± 8.04, n = 16; p=0.0001(***)). (H) Quantifications of the mean EGFP/mCherry fluorescent
intensity ratio in PL nuclei from time-lapse Video stills. Embryos were mounted in DMSO as control (n = 5) or SL327 (15 mM) (n = 5) and continuously
imaged for 12 hr starting at 54 hpf (1 hr drug treatment), finishing at 66 hpf (13 hr) (1 hr DMSO: 0.33 ± 0.02, n = 20; 1 hr SL327: 0.24 ± 0.02, n = 23;
p=0.0036 (**)) (13 hr DMSO: 0.39 ± 0.02, n = 20; 13 hr SL327: 0.26 ± 0.03, n = 16; p=0.0006(***)). (I) Quantifications of mean EGFP/mCherry Ratio in PLs
of embryos at 66 hpf treated with DMSO/SL327 for 12 hr from 54 hpf to 66 hpf without time-lapse imaging (12 hr DMSO: 0.47 ± 0.02, PLs n = 43; 13 hr
SL327: 0.37 ± 0.03, PLs n = 22; p=0.02 (*)). (J) Quantification of PL number in embryos treated with DMSO/SL327 for 12 hr at 66 hpf without time-lapse
imaging (12 hr DMSO: 8.6 ± 1.08, embryo n = 5; 13 hr SL327: 4.4 ± 0.81, embryo n = 5; p=0.014 (*)).
DOI: https://doi.org/10.7554/eLife.42881.022
The following source data and figure supplements are available for figure 5:
Source data 1. Measurements of LEC EGFP-YAP in response to Vegfc.
DOI: https://doi.org/10.7554/eLife.42881.025
Figure supplement 1. The autonomous EGFP-YAP response to Vegfc in transplanted ECs.
DOI: https://doi.org/10.7554/eLife.42881.023
Figure supplement 1—source data 1. Measurements of EGFP-YAP PLs in Vegfc-overexpression embryos.
DOI: https://doi.org/10.7554/eLife.42881.024
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Zebrafish
All zebrafish work was conducted in accordance with the guidelines of the animal ethic committee
guidelines at the University of Queensland and of the National Cerebral and Cardiovascular Center
(No.14005 and No.15010). The two different mutant strains used were the yap1ncv101-/- mutant,
which has a 25 base pair (bp) deletion in exon1 leading to a frame shift and stop codon after 71 bp,
prior to the TEAD binding domain (Nakajima et al., 2017), and the yap1mw48-/- mutant, which dis-
plays a 4 bp deletion after 158 bp, truncating the TEAD binding domain and leading to a premature
stop codon (Miesfeld et al., 2015). The transgenic zebrafish lines used were published previously as
following: Tg(fli1a:nEGFP)y7 (Lawson et al., 2002), Tg(- 5.2lyve1b:DsRed)nz101 (Okuda et al., 2012),
Tg(fli1:EGFP-YAP)ncv35 and Tg(fli1:Gal4db-TEAD2DN-2A-mC)ncv36 (Nakajima et al., 2017), Tg(UAS:
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GFP)y1 (Asakawa et al., 2008), Tg(fli1:Myr-mC)ncv1 (Kwon et al., 2013) and Tg(fli1:H2B-mC)ncv31
(Yokota et al., 2015), Tg(gata1:DsRed)sd2 (Traver et al., 2003), TgBAC(prox1a: KalTA4-4xUAS-
ADV.E1b:TagRFP)nim5(Dunworth et al., 2014; van Impel et al., 2014); Tg(10xUAS:vegfc)uq2bh
(Koltowska et al., 2015b). The Tg(fli1a:H2B-mCherry)uq37bh strain was generated for this study using
Gateway cloning and transgenesis. The transgenic line TgBAC(dab2b:EGFP)ncv67 was provided by
Shigetomo Fukuhara and Shinya Yuge (Nippon Med. School). Tg(kdrl:mCherry)ncv502 were generated
using Tol2 mediated transgenesis.
Morpholino injections
The yap1 morpholino (MO) used has been validated and described previously as MO4-yap1
(Loh et al., 2014). To control for yap1 morpholino non-specific effects, we co-injected p53 MO as
previously described (Robu et al., 2007) and both uninjected and p53 MO injected embryos were
used as controls. All MOs were purchased from Genetools, LLC and injected at 5 ng/embryo.
Genotyping of yap1 mutants
Yap1 mutants of the yap1ncv101 allele were genotyped by PCR using a Microchip Electrophoresis Sys-
tem for DNA/RNA Analysis (MCE-202 MultiNA). yap1ncv101 forward primer: TCCTTCGCAAGGC
TTGGATAATTG yap1ncv101 reverse primer: TTGTCTGGAGTGGGACTTTGGCTC yap1 mutants carry-
ing the yap1mw48 allele were genotypes using a KASP genotyping assay following the manufacturer’s
instructions (LGC Genomics).
Drug treatments and immunohistochemistry
Embryos were treated with 15 mM of the chemical inhibitor SL327 (Merk, NJ, USA) diluted in E3
medium with 0.003% 1-phenyl-2-thiourea (PTU) and 1% DMSO (Sigma) and immobilised with Tri-
caine (0.08 mg/ml) and 1% low melting agarose for imaging. Control embryos were kept in E3-PTU
water with 1% DMSO.
Immunofluorescent staining was performed as described in Okuda et al. (2018) with the follow-
ing minor changes to the protocol: 30 min of ProtK treatment (20 ng/ml) was used for 36 hpf old
embryos. For EGFP, the primary antibody used was chicken a-GFP (1:400, Abcam, #ab13970) and
secondary C1 anti-GFP (Invitrogen, #A11039). For Prox1, rabbit a-Prox1 (1:500, AngioBio, #11–002)
was used as primary and a-rabbit IgG-HRP (1:1,000, Cell Signaling, #7074S) as secondary and ampli-
fied the Prox1 signal with TSA Plus Cyanine 3 System (Perkin Elmer, #NEL744001KT).
Transplantations
EC transplantations to test cell autonomy were performed between pre-dome stage donor and host
embryos essentially as previously published (Hogan et al., 2009a). Briefly, only successfully trans-
planted embryos with a normal morphology were selected to be imaged. Despite each transplanted
graft being unique, comparable EC grafts were selected in terms of location and size for each exper-
iment. In Figure 2G–I, the EC graft size was categorized as small, medium or large to keep grafts
comparable between wildtype and mutant embryos studied. ‘Large’ grafts spanned vasculature over
4–5 somites, ‘medium’ sized grafts spanned vasculature over 2–3 somites and ‘small’ grafts over 1–2
somites. Single cell grafts were not included in the analysis. To analyse the response of PLs to locally
transplanted vegfc-overexpressing muscle cell grafts in Figure 4, only single cell muscle grafts adja-
cent to the horizontal myoseptum were considered which spanned one somite. The PL number was
quantified within the same somite. In Figure 5—figure supplement 1, selected host embryos
showed lymphatic or venous ECs as well as transplanted ECs in the dorsal aorta.
All EC graft donor embryos were in-crosses of either wildtype control or homozygous Zyap1ncv101
mutants. For the transplantation of muscle and neurons in Figure 5, donor embryos for the chosen
transgenes [TgBAC(prox1a: KalTA4-4xUAS-ADV.E1b:TagRFP)] as TP control and [TgBAC(prox1a:
KalTA4-4xUAS-ADV.E1b:TagRFP);Tg(10xUAS:vegfc)]as vegfc-OE were all heterozygous. Crosses
between Tg(fli1:EGFP-YAP)ncv35 and Tg(fli1a:H2B-mCherry)uq37bh were used to generate heterozy-
gous host embryos.
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Imaging
All imaged embryos were immobilised with tricaine (0.08 mg/ml) and mounted laterally in 1% low-
melting agarose (Sigma-Aldrich, A9414-100G) for still images and 0.7% agarose for time-lapse Vid-
eos. Zebrafish embryos were imaged at the Australian Cancer Research Foundation’s Cancer Ultra-
structure and Function Facility at the Institute for Molecular Bioscience in Brisbane, Australia using a
Zeiss LSM 710 FCS confocal microscope and an Andor Dragonfly Spinning Disc Confocal microscope
with the Zyla 4.2 sCMOS camera (exclusively for Video 2 and Figure 1—figure supplement 1F), or
at the National Cerebral and Cardiovascular Center Research Institute in Osaka, Japan on an OLYM-
PUS confocal microscope (FluoView FV1000 and FV1200). All embryos analysed for quantification of
signal intensity were heterozygous carriers for each transgene and imaged with the same imaging
settings for each experiment with neuronal and muscle transplantations being the exception.
Image processing and fluorescent intensity analysis
Images were processed with image processing software ImageJ Version 2.0.0-rc-49/1.51d (National
Institute of Health) and Imaris x64 (Version 9.0.2). For Figure 2B, the dorsal longitudinal lymphatic
vessel (DLLV) could not be scored due to interference with skin fluorescence in the TgBAC(dab2b:
EGFP) strain.
To investigate EGFP-YAP activity within ECs, we used three different approaches. The first
method, which we chose to use throughout the study examined nuclear EGFP/mCherry intensity
ratios within ECs. This analysis was performed using Imaris software to extract the average pixel
intensity spanning the entire nucleus in 3D. The nucleus was masked using the red channel
(mCherry). To represent both fluorophores in one graph for each cell track shown in Figure 1I and
Figure 1—figure supplement 1G, the mean mCherry intensity was used to normalize the graphs. In
the second method, nuclear EGFP/mCherry intensity was calculated manually in 2D on a single
z-plane using ImageJ. The chosen z-plane was determined by the centre of each PL nucleus. Intensi-
ties were extracted by thresholding the red channel. The final method calculated the nuclear to cyto-
plasm ratio of EGFP-YAP using the same manual approach with ImageJ with the addition that the
cell outline is manually drawn around each cell and the all values within the thresholded nucleus are
excluded.
For Figure 5, measurements of relative EGFP-YAP intensity, to control for the variation in trans-
gene signal between embryos, the average EGFP fluorescent intensity per pixel for individual PLs
was measured and divided by the mean of 6 DA cells measured within the same embryo. A similar
approach was used for Figure 5—figure supplement 1 with the modification that at least 3 DA cells
were averaged due to graft size limitations.
Figure 5C’ and E, Videos 2–3 and Figure 5—figure supplement 1C”-D” display the EGFP fluo-
rescence intensity as a heatmap within the PL nuclei which was generated using the Imaris surface
function for the red channel to select only the nuclei.
Quantification and statistical analysis
Graphic representation of data and statistical analysis was performed using Prism7 and Prism8
(GraphPad, version 7.0 c for Prism7 and version 8.0.1 for Prism8). All experiments were statistically
evaluated using the unpaired two-sided t-test as comparison of mean unless stated otherwise. Stars
indicate p-values as level of significance in GP style with p0.0001 (****), p0.0002 (***), p0.0021
(**), p0.332 (*), and p0.05 (not significant (ns)). All graphs with single dot scatter plots with error
bars showing mean and standard error of the mean (SEM). A pearson correlation analysis and linear
regression has been performed in Figure 1H and Figure 1—figure supplement 1C to compare the
similarity of the different methods to measure the average EGFP intensity.
The EC numbers in Figure 4C and Figure 5G and J were counted using the Spot detection algo-
rithm from Imaris. All other EC numbers were manually counted with ImageJ. The fragments of tho-
racic duct in Figure 2D and the PL abundance in Figure 3D were scored as present (1) or absent (0)
for each somite per embryo and displayed as percentage.
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